QB3

NEW YORK (GenomeWeb News) — Mission Bio, a startup founded last year to commercialize PCR-activated cell sorting (PACS) technology developed at the University of California, San Francisco and the California Institute for Quantitative Biosciences (QB3), has been awarded a pair of National Institut

Scientists from the University of California, San Francisco, and the California Institute for Quantitative Biosciences, or QB3, have published a study demonstrating how picoinjection can be used to precisely and efficiently add reagents to individual digital PCR reaction volumes

The expansion, which will quadruple the amount of incubator space that QB3 currently operates, is designed to quench the growing thirst of life science startups for incubator space at Mission Bay.

Approximately one year after Pfizer and the California Institute for Quantitative Biosciences inked a three-year, $9.5 million drug-discovery pact, the alliance is now overseeing seven projects combining scientists from various Pfizer sites and QB3-affiliated researchers at UC-San Francisco.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.